Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04298853 · ClinicalTrials.gov registry record · Phase 4
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
A Phase 4 study of Neonatal Abstinence Syndrome and Neonatal Opioid Withdrawal Syndrome, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04298853 is a Phase 4 study of Neonatal Abstinence Syndrome and Neonatal Opioid Withdrawal Syndrome that has completed, run by Indiana University. The registered enrollment target is 17 participants, below the 66-participant average among 17 other Neonatal Abstinence Syndrome trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04298853, a Phase 4 study of Neonatal Abstinence Syndrome and Neonatal Opioid Withdrawal Syndrome, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized pilot trial comparing scheduled morphine dosing with a weaning protocol to intermittent morphine dosing on an as-needed basis for newborns with neonatal abstinence syndrome.
Conditions Studied
Interventions
- DRUG Morphine PRN
- DRUG Morphine scheduled
Study Locations (1)
Indiana
- Indiana University Health Methodist Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2021-10-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04298853
The ClinicalTrials.gov registry entry for NCT04298853 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 17 other Neonatal Abstinence Syndrome trials with a reported enrollment target (74% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neonatal Abstinence Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Morphine PRN is the first listed.
NCT04298853 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT04298853 about?
NCT04298853 is a clinical study titled "Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome". Randomized pilot trial comparing scheduled morphine dosing with a weaning protocol to intermittent morphine dosing on an as-needed basis for newborns with neonatal abstinence syndrome.
What is the current status of trial NCT04298853?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2020-06-30. Estimated completion is 2021-10-01.
What conditions does trial NCT04298853 study?
This clinical trial studies the following conditions: Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Neonatal Opioid Withdrawal.
What interventions are being tested in trial NCT04298853?
The interventions under investigation include: Morphine PRN (DRUG), Morphine scheduled (DRUG).
Who is sponsoring clinical trial NCT04298853?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04298853 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neonatal Abstinence Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
ACTIVE NOT RECRUITING · Phase 4
-
Treatment of Neonatal Abstinence Syndrome
COMPLETED · Phase 4
-
An Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care (SUPPORT)
RECRUITING · NA
-
MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome
RECRUITING
-
A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
ACTIVE NOT RECRUITING · NA
-
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Neonatal Abstinence Syndrome
All registered trials for this condition
Neonatal Opioid Withdrawal Syndrome
All registered trials for this condition
Indiana
All trials with a study site in Indiana
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.